Johnson & Johnson (NYSE:JNJ) Shares Sold by TAGStone Capital Inc.

TAGStone Capital Inc. trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 22.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,594 shares of the company's stock after selling 5,148 shares during the quarter. Johnson & Johnson comprises about 1.4% of TAGStone Capital Inc.'s holdings, making the stock its 18th largest position. TAGStone Capital Inc.'s holdings in Johnson & Johnson were worth $2,918,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. South Dakota Investment Council raised its holdings in Johnson & Johnson by 0.3% during the first quarter. South Dakota Investment Council now owns 230,416 shares of the company's stock valued at $38,212,000 after acquiring an additional 769 shares during the period. Calton & Associates Inc. boosted its position in shares of Johnson & Johnson by 99.3% during the first quarter. Calton & Associates Inc. now owns 6,905 shares of the company's stock valued at $1,145,000 after buying an additional 3,440 shares during the period. Kestra Private Wealth Services LLC boosted its holdings in shares of Johnson & Johnson by 5.7% in the first quarter. Kestra Private Wealth Services LLC now owns 116,711 shares of the company's stock valued at $19,355,000 after purchasing an additional 6,303 shares during the period. Fountainhead AM LLC raised its stake in Johnson & Johnson by 17.0% in the first quarter. Fountainhead AM LLC now owns 3,962 shares of the company's stock worth $657,000 after buying an additional 575 shares in the last quarter. Finally, SNS Financial Group LLC increased its position in shares of Johnson & Johnson by 4.2% during the first quarter. SNS Financial Group LLC now owns 6,798 shares of the company's stock worth $1,127,000 after purchasing an additional 271 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on JNJ. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Royal Bank Of Canada lifted their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. UBS Group reiterated a "buy" rating and issued a $190.00 target price (up from $180.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Raymond James Financial lowered their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. Eleven investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus price target of $172.87.

Johnson & Johnson Stock Down 0.0%

Shares of JNJ traded down $0.02 during midday trading on Wednesday, reaching $167.91. The stock had a trading volume of 2,583,795 shares, compared to its average volume of 8,132,818. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The company has a market cap of $404.00 billion, a price-to-earnings ratio of 17.95, a PEG ratio of 2.09 and a beta of 0.41. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company's fifty day simple moving average is $154.29 and its two-hundred day simple moving average is $155.12.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The business's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.82 EPS. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.10%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.